
|Videos|September 22, 2016
Metastatic Lung Cancer with Jared M. Weiss, MD: Case 1
Metastatic Lung Cancer with Jared M. Weiss, MD
Advertisement
Weiss case 1:
A 65-year-old man with stage IV NSCLC.
- Tissue biopsy showed EGFR+ adenocarcinoma
- The patient was enrolled in a clinical trial of erlotinib vs erlotinib/bevacizumab
- He was treated with erlotinib for 10 months before developing asymptomatic progression, with slowly growing lesions.
- He was continued on erlotinib for 3 more months; His next scan showed rapid progression.
- Repeat bronchoscopy and mutation testing showed an acquired EGFR T790M mutation
- Patient was subsequently switched to osimertinib
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































